Pfizer gets FDA greenlight for first Covid-19 pill Paxlovid

Follow us on Google News:
 Pfizer gets FDA greenlight for first Covid-19 pill Paxlovid
Image source: Molly Woodward,Shutterstock

Highlights

  • Pfizer CEO Albert Bourla said the pill will help reduce hospitalizations and deaths.

  • Pfizer is expected to complete the delivery of 10 million Paxlovid strips by the end of next year.

  • President Biden said the government will pay US$5.29 billion to Pfizer for the order.

The US Food and Drug Administration (FDA) on Wednesday allowed Pfizer Inc (NYSE: PFE) to market its first Covid-19 pill that will enable the newly infected patients to take the treatment at home.

The authorization allows doctors to prescribe the Paxlovid drug to patients aged 12 and older. It is an important development in reducing hospitalizations and death, say experts.

Researchers expect Paxlovid would be effective against the Omicron variant.

Patrizia Cavazzoni, who heads the FDA’s drug division, described the approval as a major step forward in fighting coronavirus and would provide doctors with a new tool to combat the virus.

The company said that Paxlovid pill would be available at pharmacies and hospitals in the coming days.

The Initial supplies would be limited before it ramps up production. But President Joe Biden said the US would have more than 250,000 pills by January.

“As Pfizer works to produce these treatments as quickly as possible, we will work closely with them and provide any resource needed, including using the Defense Production Act if warranted,” he said.

Biden said that the government would pay US$5.29 billion for 10 million Paxlovid strips. Pfizer is likely to complete the delivery by the end of next year. The pills will be free for patients, he added.

Also Read: US stocks edge higher as Omicron fears fizzle

Pfizer said the Paxlovid pill would be available at pharmacies and hospitals in the coming days

Source: Pixabay

Also Read: Justworks IPO: Why investors exuded confidence in HR tech startup?

Pfizer gets FDA greenlight for first Covid-19 pill Paxlovid

Paxlovid Production

Pfizer said it would produce 120 million treatment courses by next year, up from 80 million previously forecast. It said that people would be able to take the treatment from home.

Pfizer CEO Albert Bourla said the pill would help reduce hospitalizations and deaths.

The pill will be given to individuals at high risk from the disease. The Centers for Disease Control and Prevention said the 65-year-olds and above and people with diabetes and chronic lung disease are the high-risk groups.

Pfizer pill was more effective during trials than those developed by others that are yet to receive approvals.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.

Featured Articles